Abatacept
Brand Names: Orencia
Methodology & AI Transparency ⓘ
Abatacept Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 125 mg/mL Injection, Solution and 87.5 mg/.7mL Injection, Solution under FDA code 0003-2188, 0003-2818 (manufactured/labeled by E.R.
- 2 Real-world patient consensus: Real-world cohort score of 82% across 17 de-identified Abatacept entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $185.00 mail/discount cash up to $453.25 uninsured retail (federal NADAC $1442.1928).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Abatacept): nausea (9.2%), headache (7.4%), dizziness (5.2%).
Ask our AI Specialists anything about Abatacept
Abatacept Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 125 mg/mL Injection, Solution and 87.5 mg/.7mL Injection, Solution under FDA code 0003-2188, 0003-2818 (manufactured/labeled by E.R. Squibb & Sons, L.L.C.), Abatacept delivers subcutaneous-route selective t cell costimulation modulator pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Abatacept reflects selective t cell costimulation modulator pathway engagement after subcutaneous-route dosing (125 mg/mL Injection, Solution and 87.5 mg/.7mL Injection, Solution, manufactured/labeled by E.R. Squibb & Sons, L.L.C., NDC 0003-2188, 0003-2818), supporting titratable maintenance pharmacotherapy.
With Elimination kinetics span 8 to 19 hours per Abatacept clinical pharmacology residence kinetics and Complete (~100%) parenteral systemic delivery for Abatacept (125 mg/mL Injection, Solution) bioavailability, Abatacept undergoes systemic clearance of abatacept integrates hepatic phase ii conjugation with renal filtration and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after abatacept administration.
Standard adult regimens span 125 mg/mL Injection, Solution, 87.5 mg/.7mL Injection, Solution, 250 mg/15mL Injection, Powder, Lyophilized, for Solution, 50 mg/.4mL Injection, Solution. Prescribers screen specifically against previous anaphylactoid or exfoliative reaction attributed to abatacept; clinical scenarios where selective t cell costimulation modulator exposure from abatacept poses unacceptable risk, while community micro-logs most frequently note nausea (9.2% of reports), headache (7.4% of reports), fatigue (5.5% of reports).
Verify medication reconciliation lists so Abatacept is not inadvertently duplicated with another selective t cell costimulation modulator.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Abatacept dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Abatacept
- Clinical scenarios where selective t cell costimulation modulator exposure from Abatacept poses unacceptable risk
Logged Side-Effect Incidence (17 Reports)
Abatacept Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Abatacept)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Trajectory of clinical responses in patients with early autoimmune joint pain: What a 451-Participant Study Found A high proportion of individual patients achieving clinical endpoints at IP week 24 with abatacept + methotrexate sustained their responses through week 52. Arthritis research & therapy • 2023-04-22 • Phase III Randomized Trial | N = 451 | 93/100 | PMID 37087459 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Subcutaneous Abatacept Plus Standard Treatment for Active The proportion of patients who met improvement criteria after 24 weeks was similar between abatacept and placebo groups. Arthritis & rheumatology (Hoboken, N.J.) • 2025-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39609094 ↗ |
| Can This Approach Help? Inside the Latest Research on Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Treatment with abatacept and MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL-10 levels predicted better treatment response with abatacept and MTX versus placebo and MTX across... Arthritis & rheumatology (Hoboken, N.J.) • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41733109 ↗ |
| New Insights on Absence of Association Between Abatacept Exposure and Initial Infection in: What a 343-Participant Study Found In patients aged 2-17 years with pJIA, no evidence of association between higher levels of exposure to IV ABA or SC ABA and incidence of infection was observed. The Journal of rheumatology • 2021-07-15 • Phase III Randomized Trial | N = 343 | 87/100 | PMID 33452173 ↗ |
| Can This Approach Help? Inside the Latest Research on Belatacept how the body absorbs the medicine Analysis of Belatacept Early Steroid Future studies to optimize BELA dosing strategies are warranted as BELA exposure in this analysis exceeded Phase 3 target thresholds. Clinical transplantation • 2025-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40704545 ↗ |
Abatacept Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1442.1928/unit (~$43265.78/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Abatacept Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Abatacept RxNorm Concept ID | RXN-00032188-2628 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1442.1928 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 82.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Abatacept Patient Community, Cohort Filters & Dosage Logs
Deterministic Abatacept reference combining NIH RxNorm (RXN-00032188-2628), Medicaid NADAC ($1442.1928/unit), and anonymous cohort outcomes (82% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Abatacept community threads and patient logs by age, biological sex, dosage, and treatment duration.